FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody that specifically binds to PD-1, or its antigen-binding fragment, a pharmaceutical composition containing it, as well as to a method for obtaining this antibody and its fragment. Also disclosed is the isolated nucleic acid molecule for the production of an antibody or antigen-binding part, as well as the vector and host cell containing it. The invention also relates to a method for increasing the immunity of a patient using the above antibody or its fragment.
EFFECT: invention is effective for the treatment of cancer in a patient.
30 cl, 11 dwg, 14 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| BINDING MOLECULES INDUCING CELLULAR ACTIVATION | 2019 |
|
RU2770620C1 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
